These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 23963215)

  • 1. The PCAST report on pharmaceutical innovation: implications for the FDA.
    Woodcock J
    Clin Pharmacol Ther; 2013 Sep; 94(3):297-300. PubMed ID: 23963215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PCAST report: impact and implications for the pharmaceutical industry.
    Morris SA; Rosenblatt M; Orloff JJ; Lewis-Hall F; Waldstreicher J
    Clin Pharmacol Ther; 2013 Sep; 94(3):300-2. PubMed ID: 23963216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catalyzing the Critical Path Initiative: FDA's progress in drug development activities.
    Parekh A; Buckman-Garner S; McCune S; ONeill R; Geanacopoulos M; Amur S; Clingman C; Barratt R; Rocca M; Hills I; Woodcock J
    Clin Pharmacol Ther; 2015 Mar; 97(3):221-33. PubMed ID: 25670629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reinventing bioinnovation.
    Kaitin KI; Honig PK
    Clin Pharmacol Ther; 2013 Sep; 94(3):279-83. PubMed ID: 23963211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re-engineering drug discovery and development.
    FitzGerald GA
    LDI Issue Brief; 2011 Oct; 17(2):1-4. PubMed ID: 22049582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Building a stronger foundation for a new century of treatments and cures.
    Sebelius K
    Health Aff (Millwood); 2011 Jan; 30(1):81-3. PubMed ID: 21209442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership.
    Stang PE; Ryan PB; Racoosin JA; Overhage JM; Hartzema AG; Reich C; Welebob E; Scarnecchia T; Woodcock J
    Ann Intern Med; 2010 Nov; 153(9):600-6. PubMed ID: 21041580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current FDA directives for promoting public health.
    Hayes AH
    Am J Hosp Pharm; 1982 Mar; 39(3):427-31. PubMed ID: 7072727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drugs for children and adolescents with cancer: the need for novel development pathways.
    Vassal G; Zwaan CM; Ashley D; Le Deley MC; Hargrave D; Blanc P; Adamson PC
    Lancet Oncol; 2013 Mar; 14(3):e117-24. PubMed ID: 23434337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA's compassion for desperate drug companies.
    Annas GJ
    Hastings Cent Rep; 1990; 20(1):35-7. PubMed ID: 2179165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory science and the role of the regulator in biomedical innovation.
    Honig PK; Huang SM
    Clin Pharmacol Ther; 2012 Mar; 91(3):347-52. PubMed ID: 22343804
    [No Abstract]   [Full Text] [Related]  

  • 15. Perestroika in pharma: evolution or revolution in drug development?
    FitzGerald GA
    Mt Sinai J Med; 2010; 77(4):327-32. PubMed ID: 20687177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA pharmaceutical quality oversight.
    Yu LX; Woodcock J
    Int J Pharm; 2015 Aug; 491(1-2):2-7. PubMed ID: 26027494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoliberal technocracy: explaining how and why the US Food and Drug Administration has championed pharmacogenomics.
    Hogarth S
    Soc Sci Med; 2015 Apr; 131():255-62. PubMed ID: 25661300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory watch: Characterizing the US FDA's approach to promoting transformative innovation.
    Downing NS; Krumholz HM; Ross JS; Shah ND
    Nat Rev Drug Discov; 2015 Nov; 14(11):740-1. PubMed ID: 26435528
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.